Sender Herschorn

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Angiotensin Converting Enzyme

Lower Urinary Tract Symptoms

Patient Reported

Top Venues

Neurourology and urodynamics

This page only lists publications with an associated author ORCID identifier.

Publications

Sender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, Eric Chung, Farid Abdul Hadi, Achim Steup, Budiwan Sumarsono
Safety and efficacy of an α 1 -blocker plus mirabegron compared with an α 1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis. Neurourology and urodynamics 43 (3) (2024)
Sender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, Eric Chung, Farid Abdul Hadi, Achim Steup, Budiwan Sumarsono
Safety and efficacy of an α 1 -blocker plus mirabegron compared with an α 1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis. Neurourology and urodynamics (2024)
Sender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, Eric Chung, Farid Abdul Hadi, Achim Steup, Budiwan Sumarsono
Safety and efficacy of an α 1 -blocker plus mirabegron compared with an α 1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis. Neurourology and urodynamics (2024)
Sender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, Eric Chung, Farid Abdul Hadi, Achim Steup, Budiwan Sumarsono
Safety and efficacy of an α 1 -blocker plus mirabegron compared with an α 1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis. Neurourology and urodynamics 43 (3) (2024)
Sender Herschorn, David Staskin, Carol R Schermer, Rita M Kristy, Adrian Wagg
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Drugs & aging 37 (9) (2020)